| Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. | |
| | |
MedLine Citation:
|
PMID: 16160606 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Short-term infusion of carperitide (atrial natriuretic peptide) has beneficial effects on neurohumoral factors; however, it remains unclear whether the effects are sustained for long-term infusion. To evaluate the effects of long-term infusion of carperitide on neurohumoral factors in patients with chronic congestive heart failure (CHF), we measured neurohumoral factors before and 1 hour after stopping carperitide infusion in 42 CHF patients. Carperitide infusion was continued for more than 2 days until there was symptomatic improvement of CHF. Patients were divided into 2 groups by the median value of infusion duration: group 1 (less than 7 days, n=21) and group 2 (more than 7 days, n=21). In group 1, aldosterone (ALD) and endothelin-1 (ET-1) were significantly increased after stopping carperitide. In contrast, ALD and ET-1 did not change after stopping carperitide in group 2. The molar ratio of cyclic guanosine monophosphate/atrial natriuretic peptide before stopping carperitide was significantly lower in group 2 than in group 1. Suppression of ALD and ET-1 was maintained for 7 days of carperitide infusion, but the beneficial effect on neurohumoral factors was attenuated after more than 7 days, probably through down-regulation of biologic receptors coupled with guanylate cyclase in CHF patients. |
| | |
Authors:
|
Chitose Ishikawa; Takayoshi Tsutamoto; Atsuyuki Wada; Masanori Fujii; Keijin Ohno; Hiroshi Sakai; Takashi Yamamoto; Minoru Horie |
Related Documents
:
|
17932746 - Resistance exercise: training adaptations and developing a safe exercise prescription. 15571426 - Exercise programmes for patients with chronic heart failure. 7503006 - Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of... 7521476 - Chronic versus acute effects of amiodarone on the vmax-conduction velocity relationship... 1643806 - Can life-styles of subjects with impaired glucose tolerance be changed? a feasibility s... 10468076 - Impact of limited treadmill exercise on adenosine tc-99m sestamibi single-photon emissi... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 46 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-09-14 Completed Date: 2006-02-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 513-8 Citation Subset: IM |
Affiliation:
|
Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
metabolism* Atrial Natriuretic Factor / administration & dosage, blood, therapeutic use* Blood Pressure / drug effects Cardiomyopathy, Dilated / blood, drug therapy, physiopathology Chronic Disease Cyclic GMP / blood Endothelin-1 / metabolism* Female Heart Failure / blood, drug therapy*, physiopathology Heart Rate / drug effects Humans Infusions, Intravenous Male Middle Aged Myocardial Ischemia / blood, drug therapy, physiopathology Natriuretic Peptide, Brain / blood Stroke Volume / drug effects Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Endothelin-1; 0/NPPA protein, human; 114471-18-0/Natriuretic Peptide, Brain; 52-39-1/Aldosterone; 7665-99-8/Cyclic GMP; 85637-73-6/Atrial Natriuretic Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Supplement of tetrahydrobiopterin by a gene transfer of GTP cyclohydrolase I cDNA improves vascular ...
Next Document: Involvement of c-Jun NH2 terminal kinase and p38MAPK in rapamycin-mediated inhibition of neointimal ...